Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À§ Á¡¸·¿¬°ü¸²ÇÁÁ¶Á÷ ¸²ÇÁÁ¾ÀÇ Áø´Ü°ú Ä¡·á Diagnosis and Treatment of Gastric Mucosa-associated Lymphoid Tissue Lymphoma

´ëÇѼÒÈ­±âÇÐȸÁö 2019³â 74±Ç 6È£ p.304 ~ 313
°øÀºÁ¤, Ãֱ⵷,
¼Ò¼Ó »ó¼¼Á¤º¸
°øÀºÁ¤ ( Gong Eun-Jeong ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ °­¸ª¾Æ»êº´¿ø ³»°ú

Ãֱ⵷ ( Choi Kee-Don ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ¼ÒÈ­±â³»°ú

Abstract


The stomach is the most common primary site of an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type, which is characterized by an indolent clinical course. A diagnosis of gastric MALT lymphoma requires an endoscopic biopsy that should be confirmed by an experienced pathologist. Gastric MALT lymphoma shows a variable endoscopic appearance, including erosion, erythema, discoloration, atrophy, ulcer, and subepithelial lesion. The distribution is often multifocal. Therefore, clinical suspicion and multiple biopsies are essential for an accurate diagnosis. Gastric MALT lymphoma is almost invariably associated with a Helicobacter pylori (H. pylori) infection. H. pylori eradication therapy is the mainstay of treatment, which must be delivered to all patients regardless of the H. pylori infection status or stage. For patients who have failed to achieve remission following eradication therapy, radiotherapy or chemotherapy can be considered. Radiotherapy is an effective treatment modality for a localized stage and shows excellent outcomes. In the presence of disseminated or advanced disease, chemotherapy and/or immunotherapy with the anti-CD20 monoclonal antibody, rituximab, can be applied. Treatment should be individualized according to the stage and symptoms, as well as the patients¡¯ preference. Given that the clinical course of gastric MALT lymphoma is usually indolent, watchful waiting may be an adequate strategy in selected cases where scheduled follow-up is guaranteed.

Å°¿öµå

Diagnosis; Helicobacter pylori; Lymphoma; B-cell; marginal zone; Therapeutics

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS